Fresenius Medical Care AG
XMUN:FME
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.04
42.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fresenius Medical Care AG
Fresenius Medical Care AG
Cash from Financing Activities
Fresenius Medical Care AG
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fresenius Medical Care AG
XMUN:FME
|
Cash from Financing Activities
-€2.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-52%
|
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Cash from Financing Activities
-€2.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-52%
|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Cash from Financing Activities
-€2.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Vita 34 AG
XETRA:V3V
|
Cash from Financing Activities
-€8.7m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-35%
|
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Cash from Financing Activities
-HK$102.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Synlab AG
XETRA:SYAB
|
Cash from Financing Activities
-€825.2m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fresenius Medical Care AG
Glance View
Fresenius Medical Care AG is a global leader in providing products and services for individuals undergoing dialysis as a result of chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company specializes in the development and manufacture of high-quality dialysis equipment and supplies, including dialysis machines and filters. With a network that spans over 150 countries, Fresenius operates numerous dialysis clinics, delivering essential care to a large and growing patient population. Its commitment to innovation and quality care positions it well within the healthcare sector, making it a compelling option for investors seeking exposure in the medical technology domain. As the prevalence of kidney disease rises, driven by factors such as aging populations and increasing diabetes cases, Fresenius Medical Care is poised to capitalize on this expanding marketplace. The company's robust pipeline of therapeutic solutions and its focus on integrating healthcare technologies demonstrate a proactive approach to enhancing patient outcomes. Additionally, Fresenius benefits from a diversified business model that includes both product manufacturing and direct patient care services, which provides resilience against market fluctuations. Investors looking for a company with a strong balance sheet, consistent revenue growth, and a mission-driven approach to healthcare will find Fresenius Medical Care AG to be an attractive choice in their portfolio.
See Also
What is Fresenius Medical Care AG's Cash from Financing Activities?
Cash from Financing Activities
-2.3B
EUR
Based on the financial report for Jun 30, 2024, Fresenius Medical Care AG's Cash from Financing Activities amounts to -2.3B EUR.
What is Fresenius Medical Care AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-52%
Over the last year, the Cash from Financing Activities growth was -73%. The average annual Cash from Financing Activities growth rates for Fresenius Medical Care AG have been -12% over the past three years , and -52% over the past ten years .
You don't have any saved screeners yet
